Skip to main content
Erschienen in: Der Nervenarzt 4/2017

13.03.2017 | Parkinson-Krankheit | Leitthema

Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson

verfasst von: Prof. Dr. W. H. Jost

Erschienen in: Der Nervenarzt | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Seit den 1960er Jahren wurde eine Vielzahl von Substanzklassen zur Therapie des idiopathischen Parkinson-Syndroms eingeführt. Das wichtigste und wirksamste Medikament ist L‑Dopa, immer in Kombination mit einem Decarboxylasehemmer. Daneben werden abhängig von den motorischen Symptomen, dem Alter und einer Vielzahl weiterer Faktoren Dopaminagonisten, MAO-B-Hemmer, COMT-Hemmer, NMDA-Antagonisten und sehr selten Anticholinergika eingesetzt. Erfreulicherweise gibt es innerhalb der Substanzklassen verschiedene Präparate, die auch unterschiedliche Wirkungen haben. Damit man die Vorteile der einzelnen Medikamente ausnutzen und unerwünschte Wirkungen und Wechselwirkungen vermeiden kann, muss man sich mit der komplexen Datenlagen und der Pharmakologie der Medikamente auseinandersetzen. Ein wichtiger Aspekt sind daneben Wechselwirkungen und Interaktionen. In absehbarer Zeit wird mit differenten Substanzklassen gerechnet.
Literatur
1.
Zurück zum Zitat Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem 139(Suppl. 1):325–337CrossRefPubMed Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J Neurochem 139(Suppl. 1):325–337CrossRefPubMed
2.
Zurück zum Zitat Anonymus (2002) Anticholinergic therapies in the treatment of Parkinson’s disease. Mov Disord 17:7–12CrossRef Anonymus (2002) Anticholinergic therapies in the treatment of Parkinson’s disease. Mov Disord 17:7–12CrossRef
3.
Zurück zum Zitat Jost WH, Brück C (2002) Drug interactions in the treatment of Parkinson’s disease. J Neurol 249(Suppl. 3):24–29 Jost WH, Brück C (2002) Drug interactions in the treatment of Parkinson’s disease. J Neurol 249(Suppl. 3):24–29
5.
Zurück zum Zitat Lees AJ (1994) Levodopa substitution: The gold standard. Clin Neuropharmacol 17:1–6CrossRef Lees AJ (1994) Levodopa substitution: The gold standard. Clin Neuropharmacol 17:1–6CrossRef
6.
Zurück zum Zitat Schapira AHV (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord 23(Suppl. 3):515–520CrossRef Schapira AHV (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord 23(Suppl. 3):515–520CrossRef
7.
8.
Zurück zum Zitat Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol 66:317–323CrossRefPubMed Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol 66:317–323CrossRefPubMed
9.
Zurück zum Zitat Jorga K, Fotteler B, Schmitt M et al (1997) The effect of COMT inhibition by tolcapone on tolerability and pharmakokinetics of different levodopa/benserazide formulations. Eur Neurol 38:59–67CrossRefPubMed Jorga K, Fotteler B, Schmitt M et al (1997) The effect of COMT inhibition by tolcapone on tolerability and pharmakokinetics of different levodopa/benserazide formulations. Eur Neurol 38:59–67CrossRefPubMed
10.
Zurück zum Zitat Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508CrossRefPubMed Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508CrossRefPubMed
11.
Zurück zum Zitat Nutt JG, Woodward WR, Hammerstad JP et al (1984) The „on-off“ phenomenon in Parkinson’s disease: Relation to absorption and transport. N Engl J Med 310:483–488CrossRefPubMed Nutt JG, Woodward WR, Hammerstad JP et al (1984) The „on-off“ phenomenon in Parkinson’s disease: Relation to absorption and transport. N Engl J Med 310:483–488CrossRefPubMed
12.
Zurück zum Zitat Virmani T, Tazan S, Mazzoni P et al (2016) Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease. J Clin Mov Disord 2016:8. doi:10.1186/s40734-016-0036-9 CrossRef Virmani T, Tazan S, Mazzoni P et al (2016) Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease. J Clin Mov Disord 2016:8. doi:10.​1186/​s40734-016-0036-9 CrossRef
13.
Zurück zum Zitat Verhagen Metman L, Hoff J, Mouradian M et al (1994) Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 9:463–465CrossRef Verhagen Metman L, Hoff J, Mouradian M et al (1994) Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord 9:463–465CrossRef
14.
Zurück zum Zitat Linazasoro G, Grandas F, Martinez MP et al (1999) Controlled release levodopa in Parkinson’s disease: Influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients. Clin Neuropharmacol 22:74–79CrossRefPubMed Linazasoro G, Grandas F, Martinez MP et al (1999) Controlled release levodopa in Parkinson’s disease: Influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients. Clin Neuropharmacol 22:74–79CrossRefPubMed
15.
Zurück zum Zitat Stocchi F, Hsu A, Khanna S et al (2014) Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 20:1335–1340CrossRefPubMed Stocchi F, Hsu A, Khanna S et al (2014) Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 20:1335–1340CrossRefPubMed
16.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442CrossRefPubMed Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442CrossRefPubMed
17.
Zurück zum Zitat Obeso JA, Grandas F, Vaamonde J et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39(Suppl. 2):11–19PubMed Obeso JA, Grandas F, Vaamonde J et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39(Suppl. 2):11–19PubMed
18.
Zurück zum Zitat Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol Scand 104:343–348CrossRefPubMed Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol Scand 104:343–348CrossRefPubMed
19.
Zurück zum Zitat Reddy P, Martinez-Martin P, Rizos A et al (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: Motor and nonmotor effects. Clin Neuropharmacol 35:205–207CrossRefPubMed Reddy P, Martinez-Martin P, Rizos A et al (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease: Motor and nonmotor effects. Clin Neuropharmacol 35:205–207CrossRefPubMed
20.
Zurück zum Zitat Fox SH, Katzenschlager R, Lim S‑Y et al (2011) The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(S3):2–41CrossRef Fox SH, Katzenschlager R, Lim S‑Y et al (2011) The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(S3):2–41CrossRef
21.
Zurück zum Zitat Jost WH (2014) Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf 13:447–458CrossRefPubMed Jost WH (2014) Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf 13:447–458CrossRefPubMed
22.
Zurück zum Zitat Olanow CW, Kieburtz k OP et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: A randomized, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149CrossRefPubMed Olanow CW, Kieburtz k OP et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: A randomized, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149CrossRefPubMed
23.
Zurück zum Zitat Toth C, Brown MS, Furtado S et al (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 13:1850–1859CrossRef Toth C, Brown MS, Furtado S et al (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 13:1850–1859CrossRef
24.
Zurück zum Zitat Corsini GU, Del Zompo M, Gessa GL et al (1979) Therapeutic efficacy of apomorphin combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet i:954–956CrossRef Corsini GU, Del Zompo M, Gessa GL et al (1979) Therapeutic efficacy of apomorphin combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet i:954–956CrossRef
25.
Zurück zum Zitat Tönges L, Ceballos-Baumann A, Honig H et al (2017) Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie. Fortschr Neurol Psychiatr. (in press) Tönges L, Ceballos-Baumann A, Honig H et al (2017) Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie. Fortschr Neurol Psychiatr. (in press)
26.
Zurück zum Zitat Factor SA (2004) Intermitent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology 62(Suppl. 4):12–17CrossRef Factor SA (2004) Intermitent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology 62(Suppl. 4):12–17CrossRef
27.
Zurück zum Zitat Brecht HM (1992) Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psycho-pharmaka, Bd. 5. Springer, Wien-New York, S 226–240 Brecht HM (1992) Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuro-Psycho-pharmaka, Bd. 5. Springer, Wien-New York, S 226–240
28.
Zurück zum Zitat Kvernmo T, Härtter S, Bürger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065–1078CrossRefPubMed Kvernmo T, Härtter S, Bürger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065–1078CrossRefPubMed
29.
Zurück zum Zitat Poewe W, Rascol O, Barone P et al (2011) Extended-release pramipexole in early Parkinson disease. Neurology 77:759–766CrossRefPubMed Poewe W, Rascol O, Barone P et al (2011) Extended-release pramipexole in early Parkinson disease. Neurology 77:759–766CrossRefPubMed
30.
Zurück zum Zitat Schapira AHV, Barone P, Hauser RA et al (2011) Extended-release pramipexole in advanced Parkinson disease. Neurology 77:767–774CrossRefPubMed Schapira AHV, Barone P, Hauser RA et al (2011) Extended-release pramipexole in advanced Parkinson disease. Neurology 77:767–774CrossRefPubMed
31.
Zurück zum Zitat Biglan KM, Holloway RG (2002) A review of pramipexole and its clinical utility in Parkinson’s disease. Expert Opin Pharmacother 3:197–210CrossRefPubMed Biglan KM, Holloway RG (2002) A review of pramipexole and its clinical utility in Parkinson’s disease. Expert Opin Pharmacother 3:197–210CrossRefPubMed
32.
Zurück zum Zitat Möller JC, Oertel WH, Köster J et al (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: Results from a European multicenter trial. Mov Disord 20:602–610CrossRefPubMed Möller JC, Oertel WH, Köster J et al (2005) Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: Results from a European multicenter trial. Mov Disord 20:602–610CrossRefPubMed
33.
Zurück zum Zitat Pogarell O, Gasser T, van Hilten JJ et al (2002) Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713–720CrossRefPubMedPubMedCentral Pogarell O, Gasser T, van Hilten JJ et al (2002) Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72:713–720CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284:1931–1938CrossRef Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284:1931–1938CrossRef
35.
Zurück zum Zitat Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed
36.
Zurück zum Zitat Ferrara JM, Stacy M (2008) Impulse-control disorders in Parkinson’s disease. CNS Spectr 13:690–698CrossRefPubMed Ferrara JM, Stacy M (2008) Impulse-control disorders in Parkinson’s disease. CNS Spectr 13:690–698CrossRefPubMed
37.
Zurück zum Zitat Schrag A, Keens J, Warner J (2002) Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol 9:253–257CrossRefPubMed Schrag A, Keens J, Warner J (2002) Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol 9:253–257CrossRefPubMed
38.
Zurück zum Zitat Jost WH, Angersbach D, Rascol O (2006) Clinical studies with ropinirole in Parkinson’s disease and RLS. J Neurol 253(Suppl. 4):IV/16–IV/21CrossRef Jost WH, Angersbach D, Rascol O (2006) Clinical studies with ropinirole in Parkinson’s disease and RLS. J Neurol 253(Suppl. 4):IV/16–IV/21CrossRef
39.
Zurück zum Zitat Sethi KD, O’Brien CF, Hammerstad JP et al (1998) Ropinirole for the treatment of early Parkinson’s disease. Arch Neurol 55:1211–1216CrossRefPubMed Sethi KD, O’Brien CF, Hammerstad JP et al (1998) Ropinirole for the treatment of early Parkinson’s disease. Arch Neurol 55:1211–1216CrossRefPubMed
40.
Zurück zum Zitat Güldenpfennig WM, Poole KH, Sommerville KW (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharamcol 28:106–110CrossRef Güldenpfennig WM, Poole KH, Sommerville KW (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharamcol 28:106–110CrossRef
41.
Zurück zum Zitat Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60:1721–1728CrossRef Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 60:1721–1728CrossRef
42.
Zurück zum Zitat Watts RL, Jankovic J, Waters C et al (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272–276CrossRefPubMed Watts RL, Jankovic J, Waters C et al (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272–276CrossRefPubMed
43.
Zurück zum Zitat Lewitt PA, Boroojerdi B, Surmann E, Poewe W (2013) Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: Results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 120:1069–1081CrossRefPubMed Lewitt PA, Boroojerdi B, Surmann E, Poewe W (2013) Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: Results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm 120:1069–1081CrossRefPubMed
44.
Zurück zum Zitat Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ (2007) Rotigotine transdermal system for perioperative administration. J Neural Transm 114:219–221CrossRefPubMed Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ (2007) Rotigotine transdermal system for perioperative administration. J Neural Transm 114:219–221CrossRefPubMed
45.
Zurück zum Zitat Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90–99CrossRefPubMed Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90–99CrossRefPubMed
46.
Zurück zum Zitat Rizos A, Sauerbier A, Antonini A et al (2016) A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255–1261CrossRefPubMed Rizos A, Sauerbier A, Antonini A et al (2016) A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255–1261CrossRefPubMed
47.
Zurück zum Zitat Perez-Lloret S, Rascol O (2016) Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs 30:703–717CrossRefPubMed Perez-Lloret S, Rascol O (2016) Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs 30:703–717CrossRefPubMed
48.
Zurück zum Zitat Castro-Caldas A, Delwaide P, Jost W et al (2006) The Parkinson-CONTROL study: A 1‑year, randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with L‑dopa in Parkinson’s disease. Mov Disord 21:500–509CrossRefPubMed Castro-Caldas A, Delwaide P, Jost W et al (2006) The Parkinson-CONTROL study: A 1‑year, randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with L‑dopa in Parkinson’s disease. Mov Disord 21:500–509CrossRefPubMed
49.
Zurück zum Zitat Lebrun-Frenay C, Borg M (2002) Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin 18:209–214CrossRefPubMed Lebrun-Frenay C, Borg M (2002) Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin 18:209–214CrossRefPubMed
50.
Zurück zum Zitat Gouraud A, Millaret A, Descotes J et al (2011) Piribedil-induced sleep attacks in patients without Parkinson disease: A case series. Clin Neuropharmacol 34:104–107CrossRefPubMed Gouraud A, Millaret A, Descotes J et al (2011) Piribedil-induced sleep attacks in patients without Parkinson disease: A case series. Clin Neuropharmacol 34:104–107CrossRefPubMed
51.
Zurück zum Zitat Eggert K, Öhlwein C, Kassubek J et al (2014) Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): An 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 37:116–122CrossRefPubMed Eggert K, Öhlwein C, Kassubek J et al (2014) Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): An 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 37:116–122CrossRefPubMed
52.
Zurück zum Zitat Jost W, Retzow A, Kuhn K (2010) Piribedil – ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von zwei Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. Nervenheilkunde 29:571–577 Jost W, Retzow A, Kuhn K (2010) Piribedil – ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von zwei Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. Nervenheilkunde 29:571–577
53.
Zurück zum Zitat Schwab RS, England AC Jr, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208:1163–1170CrossRef Schwab RS, England AC Jr, Poskaner DC (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc 208:1163–1170CrossRef
54.
Zurück zum Zitat Ory-Magne F, Corvol JC, Azulay JP et al (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease. Neurology 82:300–307CrossRefPubMed Ory-Magne F, Corvol JC, Azulay JP et al (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease. Neurology 82:300–307CrossRefPubMed
55.
Zurück zum Zitat Verhagen Metmann L, Del Dotto P, LePoole K et al (1999) Amantadine for levodopa-induced dyskinesias – a 1 year follow-up study. Arch Neurol 56:1383–1386CrossRef Verhagen Metmann L, Del Dotto P, LePoole K et al (1999) Amantadine for levodopa-induced dyskinesias – a 1 year follow-up study. Arch Neurol 56:1383–1386CrossRef
56.
Zurück zum Zitat Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson’s disease. Neurol Sci 22:75–76CrossRefPubMed Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson’s disease. Neurol Sci 22:75–76CrossRefPubMed
57.
Zurück zum Zitat Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson’s disease: A randomized controlled trial. PLOS ONE 5:e15298CrossRefPubMedPubMedCentral Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson’s disease: A randomized controlled trial. PLOS ONE 5:e15298CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Del Dotto P, Pavese N, Cambaccini G et al (2001) Intravenous amantadine improves levodopa induced dyskinesias: An acute double-blind placebo controlled study. Mov Disord 16:515–520CrossRefPubMed Del Dotto P, Pavese N, Cambaccini G et al (2001) Intravenous amantadine improves levodopa induced dyskinesias: An acute double-blind placebo controlled study. Mov Disord 16:515–520CrossRefPubMed
59.
Zurück zum Zitat Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, Part 1: Treatment of levodopa-induced dyskinesia. Drugs 76:759–777CrossRefPubMed Vijayakumar D, Jankovic J (2016) Drug-induced dyskinesia, Part 1: Treatment of levodopa-induced dyskinesia. Drugs 76:759–777CrossRefPubMed
61.
Zurück zum Zitat Przuntek H, Müller T (1999) Clinical efficacy of budipine in Parkinson’s disease. J Neural Transm 56(Suppl.):75–82CrossRef Przuntek H, Müller T (1999) Clinical efficacy of budipine in Parkinson’s disease. J Neural Transm 56(Suppl.):75–82CrossRef
62.
Zurück zum Zitat Fowler JS, MacGregor RR, Wolf AP et al (1987) Mapping human brain monoamine oxidase A and B with 11 C-labeled suicide inactivators and positron emission tomography. Science 235:481–485CrossRefPubMed Fowler JS, MacGregor RR, Wolf AP et al (1987) Mapping human brain monoamine oxidase A and B with 11 C-labeled suicide inactivators and positron emission tomography. Science 235:481–485CrossRefPubMed
63.
Zurück zum Zitat Fowler JS, Volkow ND, Logan J et al (1994) Slow recovery of human brain MAO after L‑deprenyl (selegiline) withdrawal. Synapse 18:86–93CrossRefPubMed Fowler JS, Volkow ND, Logan J et al (1994) Slow recovery of human brain MAO after L‑deprenyl (selegiline) withdrawal. Synapse 18:86–93CrossRefPubMed
64.
Zurück zum Zitat Dashtipour K, Chen JJ, Kani C et al (2015) Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: A cross-sectional, cohort study. Pharmacotherapy 35:681–686CrossRefPubMedPubMedCentral Dashtipour K, Chen JJ, Kani C et al (2015) Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: A cross-sectional, cohort study. Pharmacotherapy 35:681–686CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Finberg JPM, Lamersdorf I, Commissiong JW, Youdim MBH (1996) Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl 48:95–101PubMed Finberg JPM, Lamersdorf I, Commissiong JW, Youdim MBH (1996) Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl 48:95–101PubMed
66.
Zurück zum Zitat Hauser RA, Abler V, Eyal E, Eliaz RE (2016) Efficacy of rasagiline in early Parkinson’s disease: A meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci 126:942–946CrossRefPubMed Hauser RA, Abler V, Eyal E, Eliaz RE (2016) Efficacy of rasagiline in early Parkinson’s disease: A meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci 126:942–946CrossRefPubMed
67.
Zurück zum Zitat Jankovic J, Berkovich E, Eyal E, Tolosa E (2014) Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 20:640–643CrossRefPubMed Jankovic J, Berkovich E, Eyal E, Tolosa E (2014) Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord 20:640–643CrossRefPubMed
68.
Zurück zum Zitat Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 59:1937–1943CrossRef Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 59:1937–1943CrossRef
69.
Zurück zum Zitat Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561–566CrossRef Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561–566CrossRef
70.
Zurück zum Zitat Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 62:241–248CrossRef Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 62:241–248CrossRef
71.
Zurück zum Zitat Rascol O, Hauser RA, Stocchi F et al (2016) Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord 31:1489–1496CrossRefPubMed Rascol O, Hauser RA, Stocchi F et al (2016) Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord 31:1489–1496CrossRefPubMed
72.
Zurück zum Zitat Jost WH, Klasser M, Reichmann H (2008) Rasagilin im klinischen Alltag. Fortschr Neurol Psych 76:594–599CrossRef Jost WH, Klasser M, Reichmann H (2008) Rasagilin im klinischen Alltag. Fortschr Neurol Psych 76:594–599CrossRef
73.
Zurück zum Zitat Müller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm 120:761–765CrossRefPubMed Müller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm 120:761–765CrossRefPubMed
74.
Zurück zum Zitat Jost WH, Friede M, Schnitker J (2012) Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia 2:17–26CrossRef Jost WH, Friede M, Schnitker J (2012) Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia 2:17–26CrossRef
75.
Zurück zum Zitat Schapira AH (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: A review of symptomatic and potential disease-modifying effects. CNS Drugs 25:1961–1071CrossRef Schapira AH (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: A review of symptomatic and potential disease-modifying effects. CNS Drugs 25:1961–1071CrossRef
76.
Zurück zum Zitat Pålhagen S, Heinonen E, Hägglund J et al (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206CrossRefPubMed Pålhagen S, Heinonen E, Hägglund J et al (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206CrossRefPubMed
77.
Zurück zum Zitat Olanow CW, Stocchi F (2016) Safinamide – a new therapeutic option to address motor symptoms and motor complications in mid- to late-stage Parkinson’s disease. Eur Neurol Rev 11(Suppl. 2):2–15 Olanow CW, Stocchi F (2016) Safinamide – a new therapeutic option to address motor symptoms and motor complications in mid- to late-stage Parkinson’s disease. Eur Neurol Rev 11(Suppl. 2):2–15
78.
Zurück zum Zitat Marzo A, Dal Bo L, Monti NC et al (2004) Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 50:77–85CrossRefPubMed Marzo A, Dal Bo L, Monti NC et al (2004) Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 50:77–85CrossRefPubMed
79.
Zurück zum Zitat Borgohain R, Szasz J, Stanzione P et al (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237CrossRefPubMed Borgohain R, Szasz J, Stanzione P et al (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237CrossRefPubMed
80.
Zurück zum Zitat Borgohain R, Szasz J, Stanzione P et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280CrossRefPubMed Borgohain R, Szasz J, Stanzione P et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280CrossRefPubMed
81.
Zurück zum Zitat Schapira AHV, Fox S, Hauser R et al (2017) Safinamide as a levodopa adjunct in Parkinson’s disease patients with motor fluctuations: A 24-week randomized, double-blind, placebo-controlled trial. JAMA Neurol 74:216–224CrossRefPubMed Schapira AHV, Fox S, Hauser R et al (2017) Safinamide as a levodopa adjunct in Parkinson’s disease patients with motor fluctuations: A 24-week randomized, double-blind, placebo-controlled trial. JAMA Neurol 74:216–224CrossRefPubMed
82.
Zurück zum Zitat Cattaneo C, Ferla RL, Bonizzoni E, Sardina M (2015) Long-term effects of safinamide on dyskinesia in mid- to late stage Parkinson’s disease: A post-hoc analysis. J Parkinsons Dis 5:475–481CrossRefPubMedPubMedCentral Cattaneo C, Ferla RL, Bonizzoni E, Sardina M (2015) Long-term effects of safinamide on dyskinesia in mid- to late stage Parkinson’s disease: A post-hoc analysis. J Parkinsons Dis 5:475–481CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Nutt JG, Woodward WR, Gancher ST et al (1987) 3‑O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21:584–588CrossRefPubMed Nutt JG, Woodward WR, Gancher ST et al (1987) 3‑O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21:584–588CrossRefPubMed
84.
Zurück zum Zitat Keating GM, Lyseng-Williamson KA (2005) Tolcapone: A review of its use in the management of Parkinson’s disease. CNS Drugs 19:165–184CrossRefPubMed Keating GM, Lyseng-Williamson KA (2005) Tolcapone: A review of its use in the management of Parkinson’s disease. CNS Drugs 19:165–184CrossRefPubMed
85.
Zurück zum Zitat Assal F, Spahr L, Hadengue A et al (1998) Tolcapone and fulminant hepatitis. Lancet 352:958CrossRefPubMed Assal F, Spahr L, Hadengue A et al (1998) Tolcapone and fulminant hepatitis. Lancet 352:958CrossRefPubMed
86.
Zurück zum Zitat Lees AJ, Ratziu V, Tolosa E et al (2007) Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:944–948CrossRefPubMed Lees AJ, Ratziu V, Tolosa E et al (2007) Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry 78:944–948CrossRefPubMed
87.
Zurück zum Zitat Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silve P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev 13:352–379CrossRefPubMed Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silve P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev 13:352–379CrossRefPubMed
88.
Zurück zum Zitat Baas H, Zehrden F, Selzer R et al (2001) Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet 40:383–393CrossRefPubMed Baas H, Zehrden F, Selzer R et al (2001) Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet 40:383–393CrossRefPubMed
89.
Zurück zum Zitat Rocha JF, Almeida L, Falcão A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76:763–775CrossRefPubMedPubMedCentral Rocha JF, Almeida L, Falcão A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76:763–775CrossRefPubMedPubMedCentral
90.
Zurück zum Zitat Ferreira JJ, Rocha JF, Falcão A et al (2015) Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol 22:815–825CrossRefPubMed Ferreira JJ, Rocha JF, Falcão A et al (2015) Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol 22:815–825CrossRefPubMed
91.
Zurück zum Zitat Ferreira JJ, Lees A, Rocha JF et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol 15:154–165CrossRef Ferreira JJ, Lees A, Rocha JF et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol 15:154–165CrossRef
92.
Zurück zum Zitat Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurol 74:197–206CrossRefPubMed Lees AJ, Ferreira J, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurol 74:197–206CrossRefPubMed
93.
Zurück zum Zitat Nutt JG (1996) Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmcokinetics of L‑Dopa. Adv Neurol 69:493–496PubMed Nutt JG (1996) Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmcokinetics of L‑Dopa. Adv Neurol 69:493–496PubMed
94.
Zurück zum Zitat Olanow CW, Kieburtz K, Rascol O et al (2011) Time to first levodopa-induced motor complication (dyskinesia or wearing-off): Results from the STRIDE-PD study. Ann Neurol 70(S15):1–181CrossRef Olanow CW, Kieburtz K, Rascol O et al (2011) Time to first levodopa-induced motor complication (dyskinesia or wearing-off): Results from the STRIDE-PD study. Ann Neurol 70(S15):1–181CrossRef
95.
Zurück zum Zitat Talati R, Reinhart K, Baker W et al (2009) Pharmacologic treatment of advanced Parkinson’s disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 15:500–505CrossRefPubMed Talati R, Reinhart K, Baker W et al (2009) Pharmacologic treatment of advanced Parkinson’s disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 15:500–505CrossRefPubMed
96.
Zurück zum Zitat Walker RW, Howells AR, Gray WK (2011) The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord 17:27–29CrossRefPubMed Walker RW, Howells AR, Gray WK (2011) The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord 17:27–29CrossRefPubMed
97.
Zurück zum Zitat Eggert KM, Oertel WH, Reichmann H et al (2012) Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Weimar C et al (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 5. Aufl. Thieme, Stuttgart, S 124–162 Eggert KM, Oertel WH, Reichmann H et al (2012) Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Weimar C et al (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 5. Aufl. Thieme, Stuttgart, S 124–162
Metadaten
Titel
Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson
verfasst von
Prof. Dr. W. H. Jost
Publikationsdatum
13.03.2017
Verlag
Springer Medizin
Erschienen in
Der Nervenarzt / Ausgabe 4/2017
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-017-0309-z

Weitere Artikel der Ausgabe 4/2017

Der Nervenarzt 4/2017 Zur Ausgabe

Mitteilungen der DGN

Mitteilungen der DGN

Mitteilungen der DGPPN

Mitteilungen der DGPPN